Uncategorized Archives - Page 37 of 145

MondayMar 20, 2023 9:45 am

HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults

New data show rising burden of most cardiovascular risk factors among young adults aged 20 to 44 in the U.S. Findings are “extremely concerning” as expert notes “we’re witnessing a smoldering public health crisis” HeartBeam has developed the first and only 3D-vector electrocardiogram for heart attack detection anytime, anywhere A recent study shows that risk factors for cardiovascular (“CV”) disease are rising among young adults (https://ibn.fm/jvjFN). Studies like this that provide critical information regarding CV disease highlight the ongoing urgency of HeartBeam’s efforts. HeartBeam (NASDAQ: BEAT) is a cardiac technology company that has developed the first and only 3D-vector electrocardiogram…

FridayMar 17, 2023 9:45 am

Progressive Care Inc. (RXMD) Is ‘One to Watch’

Progressive Care reported a 4% year-over-year revenue increase to approximately $10.1 million for the quarter ended September 30, 2022 The company’s prescription revenue increased 16% year-over-year to almost $9.4 million during that same period In 2022, Progressive Care received nearly $6 million from a strategic investment transaction with NextPlat Corporation The company launched its ClearMetrX platform for 340B third-party administration in 2022 Progressive Care will partner with MedAvail in2023 to provide prescription dispensing kiosks Progressive Care (OTCQB: RXMD) is a health services organization based in Florida that offers personalized healthcare services and technology that supports the managed healthcare industry. Through…

MondayMar 13, 2023 10:30 am

Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression

A recent medical study found that psychedelic drugs showed promise as a treatment alternative for hard-to-treat depression Psychedelics were found to activate a greater number of serotonin 2A receptors then traditional antidepressant drugs, largely because of their ability to penetrated through cells’ fatty outer membranes The study reinforces the potential use of psychedelic drugs, and psilocybin in particular, as a treatment methodology for a variety of mental health related conditions Silo Pharma, a developmental stage biopharmaceutical company has long focused around merging traditional therapeutics with psychedelic research In a study carried out between 2013 to 2016, researchers found that 8.1%…

MondayMar 13, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders

BiondVax is a biopharmaceutical company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products, primarily for the treatment of infectious and autoimmune diseases The company is led by CEO Amir Reichman, with over 20 years of international experience as a biopharma expert Amir took company reins in 2021 and pivoted the mission and vision including diversifying risks With new focus and opportunity, BiondVax now developing an innovative alpaca-derived nanosized antibody (“NanoAb”) pipeline BiondVax is aggressively advancing new NanoAb therapeutic and prophylactic technologies owing to exclusive collaborations, previous pharma development experience and a state-of-the-art GMP manufacturing facility Leveraging top-tier pharmaceutical industry…

TuesdayMar 07, 2023 10:30 am

India Globalization Capital Inc. (NYSE American: IGC) Focused on Fighting Alzheimer’s Disease with First-of-Kind Treatments in Study Phase

Government showing strong support for bills aimed at treating Alzheimer’s disease IGC’s leading drug candidate recently completed phase 1 of a safety and tolerability trial, and entered phase 2 Company’s proprietary treatments have “the potential to revolutionize the treatment of Alzheimer’s disease” Key legislation designed to fight Alzheimer’s has been introduced in Congress — or actually reintroduced: the NAPA Reauthorization Act was first introduced in the last Congress but is seeing continued support from the current group of elected officials (https://ibn.fm/8vynv). Support for the treatment of Alzheimer’s is essential for organizations such as India Globalization Capital (NYSE American: IGC), a…

FridayMar 03, 2023 10:30 am

India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer’s Symptoms

Company’s investigational drug is being tested for the first time ever on humans in an FDA-approved study In phase 1 studies, IGC-AD1 shows potential to safely reduce debilitating symptoms IGC is actively building a portfolio of both cannabis-based and manufactured molecules that can address multiple areas of unmet medical needs In groundbreaking work that establishes its commitment to being a pioneer in the treatment of Alzheimer’s disease, India Globalization Capital (NYSE American: IGC) is developing a cannabis-based investigational drug that is being tested for the first time ever on humans in an FDA-approved study (https://ibn.fm/qsc42). The company is developing its…

FridayMar 03, 2023 9:00 am

HeartBeam Inc. (NASDAQ: BEAT) CEO Spotlighted in Interview on Making a Positive Social Impact

During interview, Vajdic recounts first steps of journey in the United States CEO points to key lessons he learned that helped him found HeartBeam The company has developed the first and only 3D-vector 12-lead electrocardiogram (“ECG”) platform for heart attack detection anytime, anywhere Growing up in Yugoslavia (now Serbia) as the only child of a well-known surgeon, HeartBeam (NASDAQ: BEAT) CEO and founder Branislav Vajdic, PhD, felt some pressure to study medicine and follow in his father’s footsteps. One day, at his father’s insistence, Vajdic observed a surgery — and fainted the moment he saw the first drop of blood.…

ThursdayMar 02, 2023 9:00 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Nano-sized Molecules Show Powerful Impact in Preclinical Studies

BiondVax Pharmaceuticals is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company’s alpaca-derived nanosized antibodies (“NanoAbs”) exhibit superior valuable competitive advantages over commercially available monoclonal antibodies (“mAbs”), including better specificity and affinity to the target, hyper-thermostability, and potential for more effective and convenient routes of administration Preclinical in vivo data have shown its lead drug candidate, the inhaled anti-SARS-CoV-2 NanoAb, led to a significantly shorter and milder illness, virtually eliminated the virus from the lungs, and effectively prevented illness when administered prophylactically BiondVax aims to fill the void in COVID-19 therapeutics and is forging ahead…

FridayFeb 24, 2023 9:45 am

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants

BiondVax is a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products The company primarily targets infectious diseases and autoimmune diseases, with its lead candidate, an inhaled COVID-19 NanoAb therapy, the subject of preclinical studies So far, the preclinical studies have shown that the NanoAb results in significantly milder illness and faster recovery, eliminates the SARS-CoV-2 virus from the lungs, and prevents illness when administered prophylactically The FDA has revoked the authorization of multiple mAb treatments and one mAb prophylactic drug, creating a significant gap in a market that has shown strong demand for COVID-19 treatments BiondVax is…

WednesdayFeb 22, 2023 9:45 am

Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders

SILO issued US Patent by USPTO titled “Pharmacological Prophylactics Against Stress-Induced Affective Disorders In Females” Claims allowed by patent protect use of SPC-15 for treating stress-induced affective disorders, including anxiety and PTSD Other therapeutics in company pipeline include SPU-16 to treat multiple sclerosis, SPU-21 to treat rheumatoid arthritis, SPC-14 to treat Alzheimer’s disease Therapeutics developed by SILO may qualify for FDA’s streamlined 505(b)(2) regulatory drug approval pathway Silo Pharma (NASDAQ: SILO), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, was recently issued US Patent 11,491,120 by the US Patent and Trademark Office (“USPTO”) (https://ibn.fm/rMLOR). The…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

HeartBeam Inc. (NASDAQ: BEAT) Focuses on CV Solutions as Study Shows CV Disease Rising Among Young Adults

Progressive Care Inc. (RXMD) Is ‘One to Watch’

Silo Pharma Inc. (NASDAQ: SILO) Set to Benefit as Study Supports the Efficacy of Psychedelics in Treating ‘Drug-Resistant’ Depression

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Leverages Top-Tier Leadership and GMP Facility to Advance Rapid Development of New Therapeutic and Prophylactic Technologies for Multiple Diseases and Disorders

India Globalization Capital Inc. (NYSE American: IGC) Focused on Fighting Alzheimer’s Disease with First-of-Kind Treatments in Study Phase

India Globalization Capital Inc. (NYSE American: IGC) Leads the Way Forward with Revolutionary Cannabis-Based Treatment for Alzheimer’s Symptoms

HeartBeam Inc. (NASDAQ: BEAT) CEO Spotlighted in Interview on Making a Positive Social Impact

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Nano-sized Molecules Show Powerful Impact in Preclinical Studies

BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) and Its Collaborators Are Positioned to Rapidly Develop COVID-19 Treatments to Neutralize Emerging Variants

Silo Pharma Inc. (NASDAQ: SILO) Granted US Patent For SPC-15 to Prevent and Treat Stress-Induced Disorders

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search